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Abstract
p120-Catenin binding to, and Hakai-mediated ubiquitination of the E-cadherin juxtamembrane domain (JMD) are thought
to be involved in regulating E-cadherin internalization and degradation. However, the relationship between these two
pathways is not understood. We targeted the E-cadherin JMD to mitochondria (WT-JMD) to isolate this domain from the
plasma membrane and internalization, and to examine protein modifications and degradation. WT-JMD localized to
mitochondria, but did not accumulate there except when proteasome activity was inhibited. We found WT-JMD was
ubiquitinated, and arginine substitution of lysines at position 5 (K5R) and 83 (K83R) resulted in the stable accumulation of
mutant JMD at mitochondria. p120-Catenin did not localize, or bind to WT-JMD even upon proteasome inhibition, whereas
the K5,83R-JMD mutant bound and localized p120-catenin to mitochondria. Mutation of the p120-catenin binding site in
combination with these lysine mutations inhibited p120-catenin binding, but did not decrease JMD stability or its
accumulation at mitochondria. Thus, increased stability of JMD lysine mutants was due to inhibition of ubiquitination and
not to p120-catenin binding. Finally, mutation of these critical lysines in full length E-cadherin had similar effects on protein
stability as WT-JMD. Our results indicate that ubiquitination of the JMD inhibits p120-catenin binding, and targets E-
cadherin for degradation.
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Introduction
The level of membrane proteins at the plasma membrane is
regulated by post-translational modifications including phosphor-
ylation and ubiquitination. For example, Epithelial Growth Factor
Receptor (EGFR) is ubiquitinated and internalized leading to the
recycling of EGFR and/or the degradation of both receptor and
its ligand (for review see [1]). In addition, both tyrosine [2,3,4] and
non-tyrosine kinase receptors [5] are ubiquitinated and degraded
in a proteasome-dependent manner. Ubiquitination and protea-
some degradation of transmembrane receptors may depend on
ligand binding in the case of Growth Hormone Receptor [4] and
Interleukin-5 [3], or not in the case of Met Tyrosine Kinase
Receptor [2] and Interleukin-9 and -2 [5]. Plasma membrane
levels of the epithelial Na
+-channel (ENaC) are regulated by
ubiquitination and internalization [6], but it is unclear whether
levels of non-receptor transmembrane proteins are also controlled
by subsequent degradation by the proteasome.
Tissue development is a dynamic process requiring stages of
stabilization and loss of cell-cell adhesion [7]. E-cadherin, a
member of the Ca
2+-dependent cadherin superfamily of cell-cell
adhesion proteins, has multiple functions at the plasma membrane
including initiation and stabilization of cell-cell adhesion, regula-
tion of the actin cytoskeleton, intracellular signaling and cell
polarization [7]. E-cadherin function and organization require
interactions with catenin family members, b-catenin and a-
catenin, which are involved in linkages to the actin cytoskeleton,
and p120-catenin which regulates E-cadherin localization to the
plasma membrane [8].
p120-Catenin was first identified as a substrate for Src
tyrosine kinase [9] and later defined as a member of the catenin
family based on sequence homology with the armadillo domain
of b-catenin [10]. The p120-catenin binding site on E-cadherin
is localized in a short amino acid sequence of 93 amino acids
(the JuxtaMembrane Domain (JMD)) that contains the octapep-
tide sequence YDEEGGGE [11]. The JMD is required for E-
cadherin stability and cell-cell adhesion [12]. Binding of p120-
catenin to the JMD is proposed to prevent E-cadherin from
being internalized and degraded [13,14,15], or recycle internal-
ized cadherin back to the plasma membrane [16]. Hakai, an
E3-ubiquitin ligase, also binds the JMD in a Src phosphoryla-
tion-dependent manner, and increases E-cadherin ubiquitination
and internalization [17]. It is not known whether ubiquitination
of the JMD and p120-catenin binding to the JMD are
independent or coupled events. In addition, it is not known if
ubiquitination of the JMD or p120-catenin binding to the JMD
is involved in E-cadherin degradation since it has been difficult
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E-cadherin/JMD internalization and/or degradation.
To isolate mechanisms involved in JMD-mediated E-cadherin
degradation, we targeted E-cadherin JMD to mitochondria to
directly examine protein-protein interactions and JMD modifica-
tions. This method allowed us to establish an in vivo protein
degradation assay to analyze the stability of JMD, JMD
ubiquitination, and JMD/p120-catenin interactions independent
of cell-cell adhesion and cell migration. We verified results from
this in vivo protein degradation assay with studies of full-length E-
cadherin stabilization at the plasma membrane. Our results
indicate that the JMD regulates the degradation of E-cadherin by
the competition between binding of p120-catenin and ubiquitina-
tion.
Results
E-Cadherin JMD Level is Regulated by Proteasomal
Degradation
The plasma membrane at cell-cell contacts is crowded with
proteins that make it difficult to discriminate binding of specific
protein complexes, and/or identify post-translational modifica-
tions. Previous studies have utilized mis-targeting of proteins to
other intracellular sites to test protein functions [18,19]. We used
this method to spatially isolate the E-cadherin JMD from the
plasma membrane in order to study protein binding and
modifications involved in E-cadherin JMD regulation.
The E-cadherin JMD, comprising 91 amino acids that include
the octapeptide domain required for p120-catenin binding
(Figure 1A), was targeted to mitochondria in MDCK cells using
the ActA peptide [19] coupled to monomeric RFP as a fluorescent
read-out of expression and localization (WT-JMD; Figure 1A- top
left). A chimera of monomeric RFP and the ActA peptide (ActA)
was used as a control (ActA; Figure 1A- top right).
Expression of WT-JMD or ActA did not affect the localization
of E-cadherin to cell-cell junctions, ZO-1 to the tight junction,
vinculin to focal adhesions, nor the microtubule or actin networks
(Figure S1A). Expression of either construct also did not affect
epithelial sheet organization and migration compared to parental
MDCK cells (Figure S1B, C). Therefore, targeting of the E-
cadherin JMD to mitochondria did not appear to affect normal
cell-cell adhesion, epithelial sheet migration, or the organization of
the cytoskeleton.
To examine protein turnover, WT-JMD and ActA stable cell
lines were created using MDCK cells (see Materials and Methods
Stable Cell Lines; [20]). Both WT-JMD and ActA stable cell lines
were incubated with cycloheximide (CHX) for up to 6 hours to
inhibit further protein synthesis and allow analysis of the rate of
degradation of existing proteins. Levels of b-catenin were used as a
control for comparison with known levels of protein degradation
[21]. At 6 hours, the level of ActA was ,60% of the starting level,
while the level of WT-JMD was ,30%. b-Catenin levels
decreased ,50% (Figure 1B, C) as shown before.
WT-JMD and ActA RFP localized to mitochondria based on
co-localization with MitoTracker (Figure S2) and mitochondrial
heat shock protein 70 (A. Hartsock, unpublished results). However,
in transiently expressing cells and three independently cloned
stable cell lines the level of ActA RFP fluorescence localized at
mitochondria was much greater than WT-JMD based on RFP
fluorescence (Figure S2) and immunofluorescence with an anti-
RFP antibody (Figure 1D).
To determine if the low level of WT-JMD fluorescence
compared to ActA was due to degradation of WT-JMD, we
inhibited the proteasome with MG-132 for up to 4 hours. We
detected increased WT-JMD RFP fluorescence (Figure 1D). For
western blot analysis, we used a lower expressing ActA stable cell
line to analyze RFP levels comparable to WT-JMD, which allowed
us to observe changes in ActA levels which may not have been
obvious in the higher expressing cell lines. Western blotting of RFP
levels revealed a 4-fold increase in WT-JMD protein in the
presence of MG-132 (*p =0.018; Figure 1E, F). There was not a
statistically significant increase in RFP upon proteasome inhibition
in ActA stable cells (Figure 1E, F). Note that ActA protein levels
did not increase upon proteasome inhibition in higher expressing
stable cell lines (Figure 5B). Thus, the low level of WT-JMD
compared to ActA was due to WT-JMD-degradation by the
proteasome.
E-Cadherin Juxtamembrane Domain is Ubiquitinated
Since the level of WT-JMD increased when the proteasome was
inhibited (Figure 1D-F), we tested whether WT-JMD was
ubiquitinated (JMD-Ub). Western blot analysis of WT-JMD cell
extracts did not reveal a slower migrating band or high molecular
weight smear corresponding to the addition of ubiquitin(s). It is
possible that WT-JMD was ubiquitinated, but deubiquitinating
enzymes in the cell extract removed ubiquitin. Therefore, proteins
were extracted from cells in the presence of N-ethylameliamide
(NEM), a non-specific inhibitor of de-ubiquitination [22]. In the
presence, but not in the absence of NEM, we detected WT-JMD
and a slower migrating band positive for RFP by Western blotting
(Figure 2A); this slower migrating protein band had an apparent
increase in molecular weight of ,7 kDa compared to WT-JMD,
consistent with the addition of one ubiquitin. We did not detect an
equivalent slower migrating band in ActA from control cell lysates
or ActA immunoprecipitates (Figure 5B; lane 3).
To test directly whether WT-JMD was ubiquitinated, ubiquitin-
HA (Ub-HA) was transiently expressed in WT-JMD stable cells.
Total proteins were extracted under normal conditions in both
mock and Ub-HA transfections, upon proteasome inhibition, or
NEM treatment (to inhibit de-ubiquitinating enzymes). Sequential
immunoblotting were performed using mouse monoclonal anti-
bodies for tubulin, and then HA. A protein smear was present
throughout the lane in whole cell lysates of WT-JMD cells
transfected with Ub-HA only after immunoblotting for HA
(Figure 2B, lanes 4–6). WT-JMD immuno-precipitates with RFP
antibody transiently expressing Ub-HA revealed a slower migrat-
ing band that reacted with both rabbit polyclonal RFP and mouse
monoclonal HA antibodies by western blotting (JMD-Ub;
Figure 2B, lane 10 and 11). This protein band was only detected
on the sequential immunoblot with the mouse monoclonal HA
antibody. Importantly, when RFP was immunoprecipitated in the
presence of NEM and then treated with the deubiquitinating
enzyme Usp2 the slower migrating band was lost in both RFP and
HA western blots (Figure 2C, lane 12), confirming that ‘‘JMD-Ub’’
was ubiquitinated. Note that DTT was added to the immunopre-
cipitates after the final wash but prior to the addition of Usp2 to
neutralize residual NEM. RFP immunoprecipitates subjected to
DTT and incubation without the addition of Usp2 did not result in
loss of the slower migrating band (JMD-Ub; Figure 2B lanes 10
and 11) further confirming JMD-Ub was ubiquitinated.
We also used a rabbit polyclonal antibody raised to the
cytoplasmic domain of E-cadherin to immunoprecipitate WT-
JMD. Western blots of E-cadherin immunoprecipitates confirmed
an increase in the level of WT-JMD upon proteasome inhibition
(Figure 2C, lanes 9, 10). Furthermore, a RFP-positive, protein
smear was present only when extractions were performed in the
presence of NEM (Figure 2C, lane 11). The slower migrating WT-
JMD band migrated at different molecular weights (JMD-Ubn)i n
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PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37476Figure 1. E-cadherin JMD Level is Regulated by Proteasomal Degradation. (A) Top: schematic representation of the Juxtamembrane
domain (JMD) expression construct (left) and ActA control construct (right). Bottom: mouse E-cadherin JMD sequences aligned to demonstrate
differences in mutations utilized in this study. Lysine to arginine mutations are denoted by rectangular boxes (K#R and Red ‘‘R’’). Red AAA denotes
mutations to abolish E-cadherin JMD/p120-catenin binding. E-cadherin octapeptide sequence required for binding p120-catenin is underlined.
Numbers above the sequence represent the amino acid position number, and the corresponding amino acid position in murine E-cadherin sequence
in parenthesis. (B) MDCK cells stably expressing ActA or WT-JMD were incubated for 6 hours with cycloheximide to determine protein turnover. b-
catenin used as a degradation control and GAPDH as a loading control. Number(s) on the side of gels represent apparent molecular weights of
protein standards (6 10
‘3). (C) Quantification of immunoblots of MDCK cells stably expressing ActA or WT-JMD in cycloheximide time course
experiment (see B). Band intensities normalized to GAPDH to account for the reduction in overall protein levels. Results were averaged (+/2 standard
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15), or more commonly a protein smear (Figure 2C, lanes 11, 13,
14). The slower migrating protein band and the smear were lost
upon incubation of immunoprecipitates with the deubiquitinating
enzyme Usp2 (Figure 2C, lanes 8 and 12; A. Hartsock,
unpublished results). While we observed that tubulin co-immuno-
precipitated with JMD when cells were treated with both MG-132
and NEM, we feel this is an artifact of NEM treatment as this only
appears upon the addition of NEM (Figure 3A and 3C) and in
control cell immunoprecipitations under the same conditions
(Figure 5B). Thus, E-cadherin immunoprecipitations indicate that
WT-JMD can be poly-ubiquitinated (Figure 2C).
Over-expression of Src or Hakai Increases JMD
Degradation
Src kinase phosphorylates E-cadherin cytoplasmic domain,
stabilizing binding of the E3 ligase Hakai to E-cadherin which
ubiquitinates the E-cadherin cytoplasmic domain [17]. However,
it is unknown whether p120-catenin binding to E-cadherin JMD is
error of the mean (s.e.m.)) from 3 different experiments (N=3). (D) Fluorescence images of MDCK cells transiently expressing RFP (ActA) or E-cadherin
JMD RFP fusion protein (WT-JMD) targeted to the mitochondria; boxed regions in ‘‘RFP’’ are shown below at a higher magnification in ‘‘RFP-inset.’’
Scale bar is 25 mm in 100X images, and 5 mm in insets. (E) WT-JMD levels increase 4-fold upon proteasome inhibition. WT-JMD migrated with an
apparent molecular weight that was ,15kDa greater than ActA. Number(s) on the side of the gels are the apparent molecular weights of protein
standards (610
‘3). (F) Quantification of immunoblot RFP protein levels averaged (+/2 s.e.m.) from 3 different experiments; *p#0.034.
doi:10.1371/journal.pone.0037476.g001
Figure 2. E-cadherin JMD is Ubiquitinated. (A) Lysates of WT-JMD stable cell lines under normal conditions, upon proteasome inhibition (MG-
132), or inhibition of deubiquitinating enzymes (NEM). Immunoblot (IB) for RFP shows a slower migrating band (JMD-Ub) in the presence of MG-132
and NEM. (B) In a separate experiment MDCK cells stably expressing WT-JMD were transiently transfected with Ub-HA where indicated. Cells were
extracted and RFP immunoprecipitations were preformed under normal conditions, upon proteasome inhibition, NEM treatment (to inhibit de-
ubiquitinating enzymes), addition of the deubiquitinating enzyme Usp2, or mock transfections. DTT was added to the immunoprecipitates after the
final was of Protein A beads but prior to the addition of Usp2, where indicated, to neutralize residual NEM. Immunoblots (IB) were performed for RFP
using a rabbit polyclonal antibody, followed by a sequential immunoblotting with antibodies specific for: 1) tubulin; and 2) HA. The slowest migrating
band (marked as JMD-Ub) that appears in the presence of NEM is positive for RFP and HA (lanes 10 and 11). HC denotes IgG heavy chain. Number(s)
on the side of the gels are the apparent molecular weights of protein standards (610
‘3). (C) Extracts from MDCK cells stably expressing WT-JMD were
immunoprecipitated (IP) for RFP and E-cadherin under normal conditions, upon proteasome inhibition, NEM treatment (to inhibit de-ubiquitinating
enzymes), or addition of the de-ubiquitinating enzyme Usp2. DTT was added to the immunoprecipitates after the final wash of Protein A beads but
prior to the addition of Usp2, where indicated, to neutralize residual NEM. A slow migrating band (lane 15) and protein smear (lanes 11, 13, and 14)
appear in E-cadherin immunoprecipitates in the presence of NEM, and collapse upon incubation with Usp2 (similar to RFP immunoprecipitates). RFP
immunoblots in lanes 11, 13, 14 & 15 show that the slower migrating band does migrates at different molecular weights indicating variable levels of
JMD ubiquitination. Number(s) on the side of the blots are the apparent molecular weights of protein standards (610
‘3). Data are representative of 3
different experiments.
doi:10.1371/journal.pone.0037476.g002
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either Src kinase (Src-GFP) or Hakai (Hakai-FLAG) in the
presence or absence of proteasomal inhibition and/or inhibition
of deubiquitination (NEM treatment), and examined WT-JMD
levels and p120-catenin binding.
Over-expression of Src-GFP decreased the amount of WT-JMD
by 50% compared to mock transfections (Figure 3A, lanes 1, 7;
Figure 3B; *p =0.042). Upon proteasome inhibition, the amount
of WT-JMD increased 2-fold in mock transfected cells and 3-fold
in Src-GFP expressing cells (Figure 3A, compare lanes 1 vs. 2, 3 vs.
4; Figure 3B). A slower migrating band similar to the ubiquitinated
protein band (Figure 2B) was observed in Src-GFP expressing cells
upon proteasome inhibition and NEM treatment (Figure 3A, lanes
10–11). This slower migrating protein was not present in
immunoprecipitates incubated with the de-ubiquitinating enzyme
Usp2 (Figure 3A, lane 12). Analysis of the level of JMD-Ub
compared to total mitochondrial targeted JMD protein (WT-JMD
+ JMD-Ub) demonstrated that upon Src-GFP expression there
were equivalent levels of JMD-Ub that were not statistically
different. However, the level of JMD-Ub was statistically greater
compared to mock transfected cells treated with a proteasome
inhibitor (p=0.05). Therefore, we conclude that JMD-Ub levels in
Src-GFP expressing cells were increased relative to total
mitochondrial targeted JMD protein.
The level of ubiquitinated WT-JMD (JMD-Ub) did not appear
to change when Src-GFP was over-expressed (Figure 3A, lanes 7–
10; Figure 3B), and was unaffected by proteasome inhibition
compared to the mock transfected control (Figure 3A, lanes 8, 10;
Figure 3. Expression of Src-GFP or Hakai-FLAG increase JMD degradation and ubiquitination. (A) MDCK cells stably expressing WT-JMD
were transiently transfected with Src-GFP. Cells were extracted and RFP immunoprecipitations (IP) were performed under normal conditions, upon
proteasome inhibition, NEM treatment (to inhibit de-ubiquitinating enzymes), or addition of the de-ubiquitinating enzyme Usp2. De-ubiquitinating
enzyme Usp2 (with DTT) was added, where indicated, to immunoprecipitates after the last step of washing Protein A beads. Membranes were
immunoblotted (IB) for RFP, GFP, p120-catenin, and tubulin. Number(s) on the side of the gels are the apparent molecular weights of protein
standards (610
‘3). (B) Quantification of immunoblots for WT-JMD upon expression of Src-GFP in WT-JMD stable cells. RFP WT-JMD band intensities
from immunoprecipitates were normalized to tubulin to account for reduction in overall protein levels as a result of transfections. *p,0.05. Results
are averaged from 3 different experiments (+/2 s.e.m.). (C) MDCK cells stably expressing WT-JMD were transiently transfected with Hakai-FLAG. Cells
were extracted and RFP immunoprecipitations (IP) were preformed under normal conditions, upon proteasome inhibition, NEM treatment (to inhibit
de-ubiquitinating enzymes), or addition of the de-ubiquitinating enzyme Usp2. De-ubiquitinating enzyme Usp2 (with DTT) was added, where
indicated, to immunoprecipitates after the last step of washing Protein A beads. Immunoblots (IB) were performed for RFP, p120-catenin and tubulin.
Numbers on the side of the gels are the apparent molecular weights of protein standards (610
‘3). (D) Quantification of the ratio of JMD-Ub level to
total mitochondrial targeted JMD protein (WT-JMD + JMD-Ub) upon expression of Hakai-FLAG in WT-JMD stable cells. Band intensities from
immunoprecipitates were normalized to tubulin. Results are averaged from 3 independent experiments (+/2 s.e.m.). *p,0.01, **p,0.001.
doi:10.1371/journal.pone.0037476.g003
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decrease in level of the two p120-catenin isoforms that co-
immunoprecipiated with WT-JMD when Src-GFP was over-
expressed (Figure 3A, lanes 9–11).
Expression of Hakai-FLAG in cells stably expressing WT-JMD
affected the level of WT-JMD ubiquitination. Hakai-FLAG
expression in WT-JMD cells decreased the level of WT-JMD
compared to mock transfections (Figure 3C, lanes 1, 3). The slower
migrating WT-JMD band in cell lysates expressing Hakai-FLAG
had the same apparent molecular weight as the slower migrating
WT-JMD (JMD-Ub) that accumulated upon inhibition of
deubiquitinating enzymes in mock transfected cells (Figure 3C,
lanes 9–11), but was absent from immunoprecipitates incubated
with the deubiquitinating enzyme Usp2 (Figure 3C, lane 12).
Similar analysis of the level of JMD-Ub as a ratio to total
mitochondrial targeted JMD protein (WT-JMD + JMD-Ub)
demonstrated that upon Hakai-FLAG expression there were
equivalent levels of JMD-Ub and that these levels were signifi-
cantly increased in comparison to mock transfected cells upon
proteasome inhibition (Figure 3D; *p,0.01, **p,0.001). This
analysis allowed us to determine that JMD-Ub levels in Hakai-
FLAG expressing cells were increased relative to total mitochon-
drial targeted JMD protein.
Western blots of p120-catenin showed a reduction in the
amount of p120-catenin bound to WT-JMD upon proteasome
inhibition in Hakai-FLAG expressing cells compared to the small
amount present in mock transfections under similar conditions
(Figure 3C, lanes 8, 10). p120-Catenin was not bound to WT-JMD
when Hakai-FLAG was over-expressed and cell lysates were
treated with NEM, or immunoprecipitates were treated with the
deubiquitinating enzyme Usp2 (Figure 3C, lanes 11–12). It should
be noted that due to antibody cross-reactivity two different p120-
catenin antibodies were used in this study. While the rabbit p120-
catenin antibody recognized two isoforms of p120-catenin (see
Figure 3A, lanes 1–6) the mouse p120-catenin antibody recognizes
three proteins (Figure 3C, lanes 1–6). It should be noted only one
strong reactive protein band was observed reproducibly with the
mouse p120-catenin 15D2 upon immunoprecipitation (Figure 3C).
The faster migrating band that cross-reacted with FLaSH co-
migrated with the protein band recognized by 15D2, and therefore
these two antibodies were used interchangeably throughout the
study. Taken together, these results show that Src-dependent
phosphorylation is sufficient for WT-JMD degradation and Hakai-
mediated ubiquitination, and that over-expression of Src and
Hakai altered the equilibrium of WT-JMD stability by targeting
more for degradation.
Lysine Mutations Inhibit WT-JMD Degradation
As an independent test that WT-JMD instability was due to
ubiquitin-dependent proteasomal degradation, we examined the
JMD sequence for lysine residues that could be targets for
ubiquitination. Two lysines are present within the JMD domain,
and they were mutated to arginine (Figure 1A): lysine 5 (K5R-
JMD) is located 17 amino acids upstream of the JMD octapeptide
domain required for p120-catenin binding, and lysine 83 (K83R-
JMD) is 52 amino acids downstream of the JMD octapeptide
domain. Double mutations of both lysines (K5, 83R-JMD) were
also examined. All constructs were transiently expressed in
MDCK cells and analyzed using RFP fluorescence as a read-out
of protein accumulation and stability.
The level of K5R-JMD appeared greater than WT-JMD, but
less than ActA (Figure 4A, compare with Figure 1D), while the
level of K83R-JMD appeared slightly higher than WT-JMD
(Figure 4A, compare with Figure 1D). The level of both K5R-
JMD and K83R-JMD appeared to increase upon proteasome
inhibition (Figure 4A). The level of the K5,83R-JMD double
mutant was similar to ActA (Figure 4A, compare with
Figure 1D), and did not appear to increase upon proteasome
inhibition (Figure 4A). Comparison of RFP protein turnover in
cells transiently expressing ActA or the lysine mutant K5,83R–
JMD demonstrated that the level of the lysine mutants
remaining (60%) as determined by RFP band intensities was
similar to ActA (55%) (Figure 4B and C). These results
demonstrate that K5 and K83 are required for ubiquitination
and proteasomal degradation of JMD.
E-Cadherin Juxtamembrane Domain does not Recruit
p120-Catenin to Mitochondria
p120-Catenin binds to the E-cadherin JMD [11], and is thought
to be required for E-cadherin stability [12]. Since WT-JMD levels
were low due to proteasomal degradation but could be stabilized
by inhibition of the proteasome (Figure 2A), we analyzed whether
p120-catenin localized with WT-JMD to mitochondria under
either of these conditions. Surprisingly, p120-catenin did not co-
localize with WT-JMD at mitochondria under either condition
(Figure 5A). A very small amount of p120-catenin co-immuno-
precipitated with WT-JMD when the proteasome was inhibited
and WT-JMD accumulated (Figure 5B, lane 11). However, this
amount was similar to background amounts of p120-catenin that
co-immunoprecipitated with both ActA, which lacks a p120-
catenin binding site, and WT-JMD upon inhibition of deubiqui-
tinating enzymes (Figure 5B, lanes 6, 12). Note that the other
catenins, b-catenin and a-catenin, also did not co-localize with
WT-JMD as expected since only a truncated cytoplasmic domain
of E-cadherin was expressed (Figure S3).
These results indicate that p120-catenin was not recruited to the
E-cadherin JMD. Surprisingly, p120-catenin was also not recruit-
ed to the E-cadherin JMD when proteasomal degradation was
inhibited. This result suggests that p120-catenin binding to WT-
JMD is inhibited.
JMD Lysine Mutations Differentially Affect p120-Catenin
Localization
In light of the fact that we could not find p120-catenin co-
localized with, or bound to WT-JMD, we asked whether increased
levels of the JMD lysine mutants were due to the lack of
ubiquitination or p120-catenin binding. Significantly, p120-
catenin clearly co-localized with K5R-JMD (Figure 6A) and
K5,83R-JMD (Figure 6C), but not with K83R-JMD (Figure 6B).
In addition, we noted a reduction in the localization of p120-
catenin at cell-cell contacts in cells expressing K5,83R-JMD
compared to non-transfected cells within the same image frame
(Figure 6C).
RFP immunoprecipitation was used to quantify the levels of the
JMD lysine mutants and examine p120-catenin binding. Tran-
siently transfected MDCK cells were extracted in the presence or
absence of proteasome inhibition. The level of WT-JMD increased
4-fold upon inhibition of the proteasome, as expected (Figure 6E,
lanes 3, 4; Figure 6E-graph; *p=0.001). The levels of ActA and
the K5,83R-JMD mutant were similar and only increased 0.3-fold
(p=0.0008) and 0.6-fold (p=0.026), respectively, upon protea-
some inhibition (Figure 6E, lanes 1, 2 and 7, 8; Figure 6E-graph).
The difference between the levels of ActA, K5,83R-JMD and WT-
JMD was statistically significant in all cases (***p#0.001). As
expected, we detected background levels of p120-catenin co-
immunoprecipitated with WT-JMD in the presence of proteasome
inhibition compared to ActA (Figure 6E, lane 12). However, we
Regulation of E-Cadherin Degradation
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K5,83R-JMD compared to WT-JMD, and this amount increased
only 0.4 fold upon proteasome inhibition (Figure 6E, lanes 11, 12
vs. 15, 16). Furthermore, we observed p120-catenin/RFP co-
localization in MDCK cells transiently expressing either K5R-
JMD (Figure S4A) or K5,83R-JMD (Figure S4C), but not K8R-
JMD (Figure S4B).
p120-Catenin Binding is not Responsible for Stability of
the JMD Lysine Mutants
Although the data thus far indicate a correlation between
increased stability of JMD and increased p120-catenin binding
to the JMD, it is also possible that increased JMD stability is
due to the lack of ubiquitination. To test whether the increased
level of K5,83R-JMD was due to loss of ubiquitination or
increased binding of p120-catenin, we mutated the binding site
for p120-catenin [12] to AAA in the K5,83R-JMD mutant
(AAA-K5,83R-JMD; Figure 1A). Western blots of whole cell
lysates revealed that the level of AAA-K5,83R-JMD increased
slightly upon proteasome inhibition (0.5-fold; p =0.021), similar
to that of ActA and K5,83R-JMD under the same conditions
(Figure 6E, lanes 5, 6; 6E-graph), and was greater than WT-
JMD (p =0.004). While p120-catenin colocalized with K5,83R-
JMD, it did not co-localize with AAA-K5,83R-JMD (Figure 6D).
Furthermore, western blots of RFP immunoprecipitates revealed
that p120-catenin was not bound to AAA-K5,83R-JMD
(Figure 6E, lanes 13, 14). It should also be noted p120-catenin
did not colocalize with RFP in MDCK cells transiently
expressing AAA-K5,83R-JMD (Figure S4D).
These results indicate that K5R-JMD contains a mutation in
the primary ubiquitination site, and that mutation of K5 within
WT-JMD allows the recruitment of p120-catenin to the JMD.
p120-Catenin Knockdown has a Limited Affect on JMD
Degradation
To test directly if p120-catenin affects WT-JMD levels, we
depleted p120-catenin by ,95% using specific siRNAs compared
to p120-catenin levels in WT-JMD and ActA stable cells treated
with scrambled siRNAs (Figure 6G; A. Hartsock, unpublished
data). The level of WT-JMD in p120-catenin knockdown cells was
65% less than that in controls (p =0.065). In the presence of
proteasome inhibition, there was a significant increase in WT-
JMD levels in both p120-catenin knockdown (**p =0.008) and
control cells (*p =0.020) (Figure 6G and graph). There was no
affect on ActA levels by p120-catenin knockdown (A. Hartsock,
unpublished data). These results indicate that accumulation of
WT-JMD upon proteasome inhibition was independent of p120-
catenin expression.
Lysine Mutations in Full Length E-cadherin and
Mitochondrial Targeted E-cadherin JMD have Similar
Effects on Protein Accumulation
To rule out the possibility that the effects of ubiquitination and
p120-catenin binding on JMD levels were due to mitochondrial
targeting, we transiently expressed full length E-cadherin tagged
with RFP in which the JMD was either wild-type sequence (WT-
FL) or contained lysine mutations (K5R-FL; K83R-FL; K5,83R-
FL; AAA-K5,83R-FL); the RFP fusion proteins were isolated by
RFP immunoprecipitation from whole cell lystates (Figure 7A).
The levels of K5R-FL, K5,83R-FL and AAA-K5,83R-FL were
twice the levels of WT-FL and K83R-FL. In addition, the level of
K5R-FL was similar to K5,83R-FL and AAA-K5,83R-FL
(Figure 7A, lanes 3, 5 and 6; Figure 7B), while K83R-FL levels
were similar to WT-FL (Figure 7A, lanes 2, 4; Figure 7B). p120-
Catenin did not co-immunoprecipitate with AAA-K5,83R-FL
Figure 4. Lysine mutations inhibit WT-JMD degradation and differentially affect WT-JMD stability. (A) RFP immunofluorescence of
MDCK cells transiently expressing K5R-JMD, K83R-JMD, or K5,83R-JMD under normal conditions (left column), or upon proteasome inhibition (+ MG-
132). Images were processed under identical conditions and from the same experiment as images in Figure 1D. Scale bar is 25 mm. (B) MDCK cells
were transiently transfected with ActA or K5,83R-JMD and incubated for 6 hours with cycloheximide, 40 hours post-transfection. Immunoblots (IB)
were performed for RFP, b-catenin and GAPDH. Number(s) on the side of the gels are the apparent molecular weights of protein standards (610
‘3).
(C) Quantification of immunoblots from MDCK cells transiently expressing ActA or K5,83R-JMD and incubated for 6 hours with cycloheximide, 40
hours post-transfection. Band intensities from post nuclear supernatants were normalized to GAPDH to account for reduction in overall protein levels.
Results are averaged from 3 independent experiments (+/2 s.e.m.).
doi:10.1371/journal.pone.0037476.g004
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lane 12). Furthermore, we observed RFP immunofluorescence in
MDCK cells either mock transfected or transiently expressing full
length E-cadherin tagged with RFP in which the JMD was either
wild-type (WT-FL) or contained lysine mutations (K5R-FL;
K83R-FL; K5,83R-FL; AAA-K5,83R-FL) (Figure 7C). To detect
transiently expressed WT-JMD-FL and K83R-FL the proteasome
was inhibited. Note these constructs localized at cell cell contacts
(Figure 7C). Together these data verify our results and conclusions
on the role of ubiquitination and p120-catenin binding in the
degradation of mitochondrial targeted E-cadherin JMD.
Discussion
Plasma membrane protein levels are regulated by post-
translational modifications such as ubiquitination, and phosphor-
ylation [2,3,4,5]. Here, we investigated the roles of ubiquitination,
phosphorylation and p120-catenin binding on targeting E-
cadherin for degradation. The results provide new insight into
the regulation of E-cadherin levels at the plasma membrane.
p120-Catenin binds the JMD in the cytoplasmic domain of E-
cadherin, and is required for E-cadherin stability at the plasma
membrane [12], although the precise role of p120-catenin in E-
Figure 5. Localization and binding of WT-JMD and p120-catenin. (A) Immunofluorescence of MDCK cells transiently expressing ActA or WT-
JMD. Images for RFP (red), p120-catenin (green) and merged are shown separately (1006). Boxed areas are shown as higher magnifications below
(RFP-, p120- and merge-inset). All images were from the same experiment and processed identically between cell lines. Scale bar is 25 mm in 1006
images, and 5 mm in insets. (B) Lysates and RFP immunoprecipitates (IP) of ActA and WT-JMD stable cell lines under normal conditions, upon
proteasome inhibition, or NEM treatment (to inhibit de-ubiquitinating enzymes). Immunoblots (IB) for RFP show: a slower migrating band (upper
band-JMD-Ub) that appears only in WT-JMD cells in the presence of MG-132 and NEM; the band identified as ActA/HC comprises a co-migrating ActA
and the IgG heavy chain (HC). Number(s) on the side of the gels are the apparent molecular weights of protein standards (610
‘3). (C) Quantification
of RFP intensities normalized to tubulin in WT-JMD stables cell lines. Data averaged from 3 independent experiments (+/2 s.e.m.), and 2
independently cloned stable cell lines; *p#0.05, **p#0.01.
doi:10.1371/journal.pone.0037476.g005
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PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e37476Figure 6. Lysine mutations differentially affect p120-catenin localization. (A-D) MDCK cells transiently expressing K5R-JMD. (A), K83R-JMD
(B), K5,83R-JMD (C) or AAA-K5,83R-JMD (D). Cells were fixed and processed for immunofluorescence for RFP and p120-catenin. Boxed areas are shown
at higher magnification below (inset). All images were from the same experiment and processed identically to those in Figure 5A. Scale bar is 25 mm
in 100x images, and 5 mm in insets. (E) MDCK cells transiently expressing ActA, WT-JMD, K5,83R-JMD or AAA-K5,83R-JMD. Lysates and RFP
immunoprecipitates (IP) were performed 40 hours post-transfection under normal conditions or upon proteasome inhibition. Immunoblots (IB) for
RFP show similar levels of ActA, K5,83R-JMD and AAA-K5,83R-JMD levels. Immunoblots for p120-catenin show that p120-catenin is co-
immunoprecipitated with K5,83R-JMD (lanes 15, 16) but not AAA-K5,83R-JMD (lanes 13, 14). Number(s) on the side are the apparent molecular
weights of proteins standards (610
‘3). Quantification of RFP immunoblots from cell lines transiently expressing ActA, WT-JMD, K5,83R-JMD or AAA-
K5,83R-JMD. RFP levels for ActA, K5,83R-JMD and AAA-K5,83R-JMD were higher than WT-JMD. Data are averaged from 3 independent experiments (+/
2 s.e.m.); *p =0.031, **p,0.005, ***p#0.001. (F) RFP immunofluorescence of MDCK cells transiently expressing AAA-K5,83R-JMD under normal
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e37476cadherin stabilization is unclear. The JMD domain also binds to,
and is ubiquitinated by the E3 ligase Hakai in a Src-dependent
manner, which results in internalization of E-cadherin from the
plasma membrane [17]. It is unclear whether or not JMD binding
to p120-catenin and JMD ubiquitination are mechanistically
linked, and whether pathways controlling internalization and
degradation are similar or different. Here, we targeted E-cadherin
JMD to mitochondria to isolate JMD protein-protein interaction
and protein modifications in vivo that were dependent upon JMD
recruitment of p120-catenin, Hakai and Src to the mitochondria.
Importantly, we found little or no affect of expression of
mitochondrial targeted WT-JMD on endogenous E-cadherin, b-
catenin and a-catenin levels, nor the organization or migration of
an epithelial sheet. Therefore, this approach did not appear to
affect the cell generally, and thus could be used as an in vivo assay
for JMD binding to p120-catenin compared to JMD ubiquitina-
tion, and the consequences on JMD degradation.
conditions or upon proteasome inhibition (+MG-132). Images were taken and processed under identical conditions to each other and those in
Figure 1D and Figure 4A. Scale bar is 25 mm. (G) MDCK cells stably expressing ActA or WT-JMD were transfected with either scrambled siRNAs (-) or
p120-catenin specific siRNAs (+). Cells were extracted and RFP immunoprecipitations were preformed under normal conditions or upon proteasome
inhibition (MG-132). Immunoblots (IB) were processed for RFP, p120-catenin and tubulin. Number(s) on the side of the gels are the apparent
molecular weights of protein standards (6 10
‘3). Quantification of WT-JMD levels upon knockdown of p120-catenin was normalized to tubulin.
Results are averaged from 3 independent experiments (+/2 s.e.m.); *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0037476.g006
Figure 7. Analysis of full length E-cadherin lysine mutants verifies results of RFP-JMD mitochondrial degradation assay. (A) Parental
MDCK cells and MDCK cells transiently expressing full length E-cadherin RFP fusion proteins (WT-FL), or full length E-cadherin RFP fusion proteins
containing lysine mutant sequences (K5R-FL; K83R-FL; K5,83R-FL; AAA-K5,83R-FL). RFP immunoprecipitates were performed 40 hours post-
transfection under normal conditions. Immunoblots (IB) for RFP show higher levels of K5R-FL, K5,83R-FL and AAA-K5,83R-FL compared to WT-FL.
Immunoblots for p120-catenin show that p120-catenin is co-immunoprecipitated with all E-cadherin mutants, except AAA-K5,83R-FL. (B)
Quantification of levels of transiently expressed E-cadherin RFP fusion proteins in MDCK cells. RFP band intensities were normalized to tubulin.
Results are averaged from 3–4 different experiments as indicated (+/2 s.e.m.);
‘ p,0.03, *p,0.01, **p,0.001, ***p,0.0001. (C) RFP
immunofluorescence of MDCK cells transiently mock transfected, or expressing WT-JMD-FL, K5R-WT-FL, K83R-FL, K5,83R-FL or AAA-K5,83R-FL. All
images were taken in cells in which the proteasome was inhibited (+MG-132) to ensure visualization of RFP in WT-JMD-FL and K83R-FL transiently
expressing cell lines. Images were taken and processed under identical conditions to each other. Scale bar is 25 mm.
doi:10.1371/journal.pone.0037476.g007
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sequence within E-cadherin JMD [11], we found that WT-JMD
did not bind p120-catenin, despite a large cytoplasmic pool of
p120-catenin, and was degraded rapidly. Proteasome inhibition
resulted in WT-JMD accumulation, but p120-catenin was neither
recruited to mitochondria, nor co-immunoprecipitated with WT-
JMD. While it is possible that the RFP tag on the JMD could
inhibit p120-catenin binding, we found p120-catenin was recruit-
ed and co-immunoprecipitated with mitochondrial targeted K5R-
JMD and K5,83R-JMD mutants and all full length E-cadherin
RFP fusion proteins. Thus, p120-catenin recruitment and binding
can occur in the presence of the RFP tag. It is more likely that
p120-catenin binding to WT-JMD was inhibited by a modifica-
tion(s) that targeted WT-JMD for degradation by the proteasome.
When we examined WT-JMD for ubiquitination in the
presence of NEM or Ub-HA, we detected a small amount of
ubiquitinated protein (JMD-Ub), which was sensitive to the
deubiquitination enzyme Usp2. The bulk of WT-JMD under
any of these conditions did not appear to be ubiquitinated but still
did not bind p120-catenin. We suggest that WT-JMD was
ubiquitinated in cells, but deubiquitinating enzymes were released
upon cell lysis and deubiquitinated most of the WT-JMD, even in
the presence of NEM. We cannot rule out other modifications of
JMD such as tyrosine phosphorylation that might have additional
effects on sterically inhibiting JMD/p120-catenin binding.
Significantly, p120-catenin was recruited to the JMD that had
mutations of specific lysine residues (K5R-JMD and K5,83R-
JMD). These mutations blocked JMD degradation and resulted in
JMD accumulation. We showed that K5R-JMD was sufficient to
inhibit proteasomal degradation of JMD, and result in p120-
catenin binding to either mitochondrial targeted JMD or full
length E-cadherin K5R mutants. An additional mutant AAA-
K5,83R deleted the p120-catenin binding site in combination with
both lysine mutations and also resulted in accumulation of JMD,
but, as expected, did not recruit p120-catenin. Therefore,
stabilization and accumulation of JMD was conferred by the
lysine mutations that resulted in inhibition of JMD degradation,
and not binding of p120-catenin.
The K5R mutation is 17 amino acids upstream of the p120-
catenin binding site and increased the stability of the JMD to a
greater extent than K83R, which is closer to the b-catenin binding
domain of the E-cadherin cytoplasmic tail. We suggest that p120-
catenin binding to JMD might, therefore, depend on the state of
K5 ubiquitination; the lack of ubiquitination in K5R mutants
allows p120-catenin binding, whereas the addition of an ubiquitin
to wild-type K5 might sterically inhibit p120-catenin binding.
Further in vitro studies of JMD and p120-catenin binding will be
needed to fully test this possibility.
Previous studies expressed a truncated E-cadherin containing
the extracellular domain and only the first 15 amino acids of the
JMD, which included K5. This mutant E-cadherin did not
accumulate within the plasma membrane, but instead colocalized
with endocytic markers [23]. However, this mutant E-cadherin did
not contain the octapeptide required for E-cadherin/p120-catenin
binding [11], or the two tyrosine residues required to stabilize E-
cadherin/Hakai binding [17]. Hence it is not possible to draw
conclusions about the role of p120-catein or Hakai binding on the
distribution of that mutant E-cadherin.
It has been proposed that the E3 ligase Hakai ubiquitinates E-
cadherin in a Src-dependent manner and p120-catenin is not
bound during this process [17]. However, it was not shown
directly whether Hakai or Src activity and subsequent JMD
ubiquitination affected JMD/p120-catenin binding. While we
cannot rule out that Src over-expression directly affected the state
of p120-catenin phosphorylation and hence increased the degra-
dation of WT-JMD, we demonstrated that increased expression of
Src-GFP or Hakai-FLAG alone increased WT-JMD degradation.
Furthermore, the results of our E-cadherin JMD degradation assay
showed that over-expression of either Src or Hakai resulted in
increased ubiquitination and degradation of WT-JMD.
These data, combined with p120-catenin binding to mutant
K5R-JMD, further indicate that once ubiquitination of K5 has
occurred p120-catenin cannot bind to E-cadherin and thereby
confer stability to E-cadherin. On the other hand, binding of
p120-catenin to the JMD might mask the primary ubiquitination
site in E-cadherin (K5) thereby preventing ubiquitination,
internalization and degradation. Since Hakai binds E-cadherin
JMD [17], our data support the hypothesis that Hakai may be in
competition with p120-catenin for binding the JMD. Further in
vitro binding studies will be needed to test this hypothesis directly.
With the close proximity of p120-catenin and ubiquitination
sites in the JMD it is difficult to determine exactly how p120-
catenin confers stability on E-cadherin. The E-cadherin-JMD/
p120-catenin binding interface includes a static region of protein-
protein interaction that contains the highly conserved octapeptide
sequence, and a more dynamic region upstream containing K5
[24]. It was proposed the N-terminal of p120-catetin interacts
weakly with this dynamic region of E-cadherin JMD thereby
competing binding with clathrin-mediated endocytic machinery.
Furthermore, it was suggested this interaction might be reduced by
phosphorylation of p120-catenin, which might further expose
conserved tyrosine residues in the E-cadherin JMD to Src kinase
[24]. In our studies, however, we showed that mutations of both
K5 and K83 inhibited E-cadherin degradation even in the absence
of p120-catenin binding (AAA-K5,83R). In addition, we showed
that WT-JMD accumulated upon proteasome inhibition in cells in
which p120-catenin levels were reduced ,95%. Combined, our
results indicate p120-catenin binding is not involved in WT-JMD
ubiquitin-dependent degradation. Furthermore, our analysis of the
K5 and K83 mutations in full length E-cadherin indicate this
mechanism is involved in maintaining the equilibrium of E-
cadherin localization and stability at the plasma membrane. Our
results indicate that E-cadherin can be mono- and poly-
ubiquitinated, and it is possible that both combination of
ubiquitination are responsible for targeting E-cadherin for
proteasomal degradation.
Our results support the hypothesis that competitive binding
between p120-catenin and modifications of E-cadherin by Hakai
(ubiquitination) or Src (tyrosine phosphorylation) at the JMD
regulate E-cadherin degradation. While it is possible that p120-
catenin binding to the JMD may inhibit Src or Hakai binding and
hence ubiquitination and degradation, our results show that
ubiquitination on at least K5 inhibits p120-catenin binding, and
results in proteasomal degradation of E-cadherin. In a broader
context, ubiquitination of E-cadherin JMD may block or even
displace p120-catenin, resulting in E-cadherin internalization from
the plasma membrane and rapid proteasomal degradation.
Materials and Methods
cDNA Constructs
ActA-RFP [18] was used as a control. WT-JMD was created by
sub-cloning mouse E-cadherin JMD from the cytoplasmic domain
of E-cadherin [25] into b-catenin-ActA [18] using EcoRI at the 39
end and BamHI at the 59 end (FP:GGGAATTCCGCCACCA-
TGCGGTACCTCAGAAC;
RP:CCGGATCCCCTCCTCCTGCCGTGGGGTCG). Muta-
tions were made using Stratagene QuickChangeH site directed
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primers were the exact reverse compliment of the forward primers.
K5R: AGAA-CGGTGGTCAGAGAGCCCCTGCTGCCAC-
CAGA, K83R: GATGAAAACCTGAGG-GCAGCC-GA-
CAGCGACCCC. Double mutations were made in tandem.
AAA-K5,83R was made using K5,83R as a base construct (AAA
FP: GGAGGTGGAGCAGCAGCC-CAGGACTTTGATTT-
GAGC). All mutations were verified by sequencing. Ub-HA was
a gift from Dr. Z. Chen (University of Texas Southwestern
Medical Center, Dallas, TX). Src-GFP was a gift from Dr.
Michael Way (Cancer Research, London, UK). Hakai-FLAG was
a gift from Dr. Y. Fujita (University College London, UK).
Stable Cell Lines
Cell lines were maintained in Dulbecco’s modified Eagle’s
medium (DMEM; Life Technologies) supplemented with 10%
FBS (Cell Generations). MDCK cells [20] were transfected with
ActA or WT-JMD plasmid using LipofectAMINE 2000 (Invitro-
gen) according to the manufacturer’s instructions as described
previously [18]. Cells were sorted for RFP expression using
Fluorescence Activated Cell Sorting (FACS) to increase the
number of positive RFP cells, and then selected with 0.3 mg/ml
of G418 for 10–14 days. Cells positive for RFP were plated at
single cell density, and single cell clones were isolated using cloning
rings, expanded and replicates were frozen and stored in liquid
nitrogen. The use of DNA and generation of cell lines is approved
by Stanford APLAC (Administrative Panel on Laboratory Animal
Care).
Transient Transfections
MDCK cells were transfected with plasmids (ActA, WT-JMD,
K5R-JMD, K83R-JMD, K5,83R-JMD, and AAA-K5,83R-JMD)
using LipofectAMINE 2000 (Invitrogen) according to manufac-
turer’s instructions. Cells were plated for 40 hours prior to
experiments. All transiently transfected cell lines were transfected
on the same day and time for direct comparison between all cell
lines. Ub-HA, Hakai-FLAG and Src-GFP were transfected into
WT-JMD cell line. Mock transfections were performed with
transfection reagents only.
siRNA
MDCK cells were incubated with siRNAs using LipofectA-
MINE 2000 (Invitrogen). Scrambled siRNA was siGENOME
non-targeting siRNA #3 (Dharmacon siRNA Technologies;
catalog # D-001210-03), p120-Catenin siRNA utilized the
sequence CAGUCAAGAAAGUG-GUGAAUU (Dharmacon
siRNA Technologies). 100 ng of siRNA was transfected with
10 ul of lipofectAMINE in a final volume of 200 ul in reduced
serum media. Medium was replaced 24 hours post-transfection
with DMEM, 10% FBS without antibiotics.
Immunofluorescence Microscopy
Stable cell lines were plated on collagen I-coated coverslips and
grown for 40 hours. Transiently transfected cells were plated on
collagen I-coated coverslips 6 hours post-transfection and grown
for 40 hours. Coverslips were rinsed with PBS-ME and fixed in
3% paraformaldehyde in PBS-ME for 13 minutes at room
temperature (RT). After washing, cells were incubated in 0.5%
saponin in PBS-ME for 15 minutes, followed by blocking buffer
(1% goat serum, 0.1% saponin in PBS-ME) for 1 hr at RT. Cells
were incubated with primary antibodies in blocking buffer
overnight at 4uC, washed in PBS-ME, incubated with the
secondary antibody for 30 min at RT, and washed in PBS-ME.
The following antibodies were used: rabbit RFP (Rockland;
catalog # 600-401-379; 1:500); p120-catenin (15D2; gift from Dr.
Al Reynolds, Vanderbilt University; 1:750); mouse E-cadherin
antibody raised to extracellular domain (mRR1; cells were gift
from Dr. Barry Gumbiner, University of Virginia; 1:100); mouse
ZO-1 (Zymed; catalog # 33–9100; 1:500); mouse vinculin (Sigma;
catalog # V4505; 1:100); mouse tubulin (Sigma; catalog # T6199;
1:1000); mouse b-catenin (Transducin; catalog # C19220; 1:500);
mouse a-catenin (Alexis Corp; catalog # 804-101-C100; 1:100).
Secondary antibodies used were FITC-conjugated goat anti-
mouse antibody (Jackson ImmunoResearch; catalog # 111-295-
144; 1:100) and Rhodamine-conjugated goat anti-rabbit antibody
(Jackson ImmunoResearch; catalog # 115-095-146; 1:100). Cells
were mounted in Vectashield containing DAPI. Images of
antibody-stained cells were taken using a Zeiss Axiovert 200
microscope and Axiovision software (Carl Zeiss Micro-Imaging,
Inc.). All images within an experiment were taken using the same
exposure on the same day. Images were adjusted identically within
the same experiment using Adobe Photoshop to optimize image
quality.
Cell Extraction/Immunoprecipitations
All extractions were performed at 4uC. Cells were washed twice
in TBS. Cells were extracted with 0.1% Triton X-100 in CSK
buffer (50 mM NaCl, 300 mM sucrose, 10 mM Pipes, pH 6.8,
3 mM MgCl2) with 0.1 ug/ml Pefabloc. RFP containing protein
chimeras were immunoprecipitated using a rabbit polyclonal RFP
antibody at 1:100 dilution (Clonetech; catalog # 632397). E-
cadherin immunoprecipitations used E2 antibody raised against
the cytoplasmic domain of E-cadherin [26]. Cells were incubated
with 10 mM MG-132 for 4 hours prior to extraction. 100 mM
cycloheximide (CHX) was added to cell culture media for up to 6
hours prior to extraction. NEM was resuspended in ethanol and
used at 10 mM final concentration in extraction buffer; control
extractions were performed using an equivalent volume of ethanol.
For Usp2 treatments of immunoprecipitates, antibody-protein
complexes isolated on Protein A beads in CSK buffer were
incubated with Usp2 (5 mg- gift from Dr. Ron Kopito, Stanford
University) at 37uC for 30 minutes. 1 mM DTT was added to
beads after the final wash in CSK buffer prior to incubation of
Usp2 to neutralize residual NEM activity. Proteins were processed
for SDS-PAGE, separated in BioRAD 3-8% Tris Acetate gradient
gels, and transferred overnight to PVDF membranes.
Western Blot Analysis
PVDF membranes were incubated in blocking buffer (5% milk,
2% BSA, 1% goat serum in TBS) for 1 hr at RT. Blots were
incubated with antibodies overnight at 4uC. The following
antibodies were used: rabbit RFP (Rockland; catalog # 600-
401-379; 1:500), p120-catenin (15D2; gift from Dr. Al Reynolds,
Vanderbilt University; 1:500), mouse tubulin (Sigma; catalog #
T6199; 1:2000), mouse b-catenin (Transducin; catalog # C19220;
1:500), mouse HA.11 (Covance; catalog # MMS-101P-500),
mouse GFP (Clonetech; catalog # 623375; 1:100). Secondary
antibodies used were goat anti mouse 800CW (1:15,000, LI-COR
Biosciences) and goat anti-rabbit Alexa Fluor (1:15,000, Invitro-
gen). Membranes were scanned using an Odyssey imager and
software (LI-COR Biosciences) and bands were quantified using
Image J. Resulting images of entire blots were adjusted using
Adobe Photoshop and cropped only after all adjustments were
performed. In all cases an n of 1 is equivalent to analysis from 1 gel
and subsequent blot.
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Cells were trypsinized and resuspended in low calcium media
(10% FBS, 5 uM Ca
2+ in DMEM) and plated to confluency on
collagen I-coated 35 mm glass bottom dishes (MatTek) for 75
minutes. Medium was replaced with DMEM containing 1.8 mM
Ca
2+ and incubated for 3hours. A single scratch was made along
the length of the dish using a 1 ml pipette tip and the media was
replaced with imaging media (10% FBS, 25 mM Hepes, in
DMEM without phenol red). Cells were imaged at 10X
magnification every 15 min for 15 hours at 37uC on an inverted
microscope (Axiovert 200 M) controlled with Slidebook software
(Intelligent Imaging Innovations); 5 sites were imaged along the
wound edge. The total wound area covered was quantified using
Image J software. Time zero was 15 min post-scratch.
Supporting Information
Figure S1 Expression of WT-JMD does not affect
protein localization or cell organization. (A) Immunoflu-
orescence images of MDCK stably expressing ActA or WT-JMD.
Cells were fixed and labeled for E-cadherin, ZO-1, vinculin,
tubulin, phalloidin (green) and RFP (red). All images were from
the same experiment and processed identically between cell lines.
Scale bar is 25 mm in 100X images. (B) Still images of MDCK
cells and MDCK cells stably expressing either ActA or WT-JMD
at 0 and 15 hours of wound healing assays. Scale bar is 100 mmi n
10X images (C) Quantification of total area covered during 15
hours of a wound healing assay of MDCK cells, and MDCK cells
stably expressing either ActA or WT-JMD.
(TIF)
Figure S2 ActA and WT-JMD localize at mitochondria.
(A) Endogenous RFP fluorescence of MDCK cells stably
expressing ActA or WT-JMD under normal conditions and upon
proteasome inhibition. Mitotracker was used to identify mito-
chondria. Images were taken on the same day at the same
exposure, and brightness and contrast were adjusted identically
between cell lines to demonstrate locazlization of RFP with
mitochondria. Scale bar is 25 mm in 100X images.
(TIF)
Figure S3 b- and a-Catenin do not localize at mitochon-
dria. (A-B) b-catenin (A-green) or a-catenin (B-green) and RFP
(red) immunofluorescence images of MDCK cells stably expressing
ActA or WT-JMD under normal conditions and upon proteasome
inhibition. Images were taken and processed under identical
conditions. Scale bar is 25 mm in 100X images.
(TIF)
Figure S4 Lysine Mutations Differentially Affect p120-
catenin localization. (A-D) MDCK cells were transiently
transfected with either K5R-JMD (A), K83R-JMD (B), K5,83R-
JMD (C) or AAA-K5,83R-JMD (D). Cells were fixed and
processed for immunofluorescence for RFP and p120-catenin.
Insets are cropped area denoted in 100X images (A, C). All images
were from the same experiment and processed identically. Scale
bar is 25 mm in 100X images and 5 mm in insets.
(TIF)
Acknowledgments
We thank Dr. Al Reynolds (Vanderbilt University) who generously
provided antibodies to p120-catenin.
Author Contributions
Conceived and designed the experiments: AH WJN. Performed the
experiments: AH. Analyzed the data: AH. Contributed reagents/
materials/analysis tools: AH WJN. Wrote the paper: AH WJN. Obtained
p120-catenin antibody from Albert Reynolds: WJN.
References
1. Marmor MD, Yarden Y (2004) Role of protein ubiquitylation in regulating
endocytosis of receptor tyrosine kinases. Oncogene 23: 2057–2070.
2. Jeffers M, Taylor GA, Weidner KM, Omura S, Vande Woude GF (1997)
Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome
pathway. Mol Cell Biol 17: 799–808.
3. Martinez-Moczygemba M, Huston DP (2001) Proteasomal regulation of betac
signaling reveals a novel mechanism for cytokine receptor heterotypic
desensitization. J Clin Invest 108: 1797–1806.
4. van Kerkhof P, Govers R, Alves dos Santos CM, Strous GJ (2000) Endocytosis
and degradation of the growth hormone receptor are proteasome-dependent.
J Biol Chem 275: 1575–1580.
5. Yen CH, Yang YC, Ruscetti SK, Kirken RA, Dai RM, et al. (2000) Involvement
of the ubiquitin-proteasome pathway in the degradation of nontyrosine kinase-
type cytokine receptors of IL-9, IL-2, and erythropoietin. J Immunol 165:
6372–6380.
6. Staub O, Gautschi I, Ishikawa T, Breitschopf K, Ciechanover A, et al. (1997)
Regulation of stability and function of the epithelial Na+ channel (ENaC) by
ubiquitination. EMBO J 16: 6325–6336.
7. Halbleib JM, Nelson WJ (2006) Cadherins in development: cell adhesion,
sorting, and tissue morphogenesis. Genes Dev 20: 3199–3214.
8. Hartsock A, Nelson WJ (2008) Adherens and tight junctions: structure, function
and connections to the actin cytoskeleton. Biochim Biophys Acta 1778: 660–669.
9. Reynolds AB, Roesel DJ, Kanner SB, Parsons JT (1989) Transformation-specific
tyrosine phosphorylation of a novel cellular protein in chicken cells expressing
oncogenic variants of the avian cellular src gene. Mol Cell Biol 9: 629–638.
10. Reynolds AB, Herbert L, Cleveland JL, Berg ST, Gaut JR (1992) p120, a novel
substrate of protein tyrosine kinase receptors and of p60v-src, is related to
cadherin-binding factors beta-catenin, plakoglobin and armadillo. Oncogene 7:
2439–2445.
11. Ferber A, Yaen C, Sarmiento E, Martinez J (2002) An octapeptide in the
juxtamembrane domain of VE-cadherin is important for p120ctn binding and
cell proliferation. Exp Cell Res 274: 35–44.
12. Thoreson MA, Anastasiadis PZ, Daniel JM, Ireton RC, Wheelock MJ, et al.
(2000) Selective uncoupling of p120(ctn) from E-cadherin disrupts strong
adhesion. J Cell Biol 148: 189–202.
13. Davis MA, Ireton RC, Reynolds AB (2003) A core function for p120-catenin in
cadherin turnover. J Cell Biol 163: 525–534.
14. Maeda M, Johnson E, Mandal SH, Lawson KR, Keim SA, et al. (2006)
Expression of inappropriate cadherins by epithelial tumor cells promotes
endocytosis and degradation of E-cadherin via competition for p120(ctn).
Oncogene 25: 4595–4604.
15. Xiao K, Allison DF, Buckley KM, Kottke MD, Vincent PA, et al. (2003)
Cellular levels of p120 catenin function as a set point for cadherin expression
levels in microvascular endothelial cells. J Cell Biol 163: 535–545.
16. Xiao K, Garner J, Buckley KM, Vincent PA, Chiasson CM, et al. (2005) p120-
Catenin regulates clathrin-dependent endocytosis of VE-cadherin. Mol Biol Cell
16: 5141–5151.
17. Fujita Y, Krause G, Scheffner M, Zechner D, Leddy HE, et al. (2002) Hakai,
a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin
complex. Nat Cell Biol 4: 222–231.
18. Benjamin JM, Kwiatkowski AV, Yang C, Korobova F, Pokutta S, et al. (2010)
AlphaE-catenin regulates actin dynamics independently of cadherin-mediated
cell-cell adhesion. J Cell Biol 189: 339–352.
19. Niebuhr K, Ebel F, Frank R, Reinhard M, Domann E, et al. (1997) A novel
proline-rich motif present in ActA of Listeria monocytogenes and cytoskeletal
proteins is the ligand for the EVH1 domain, a protein module present in the
Ena/VASP family. EMBO J 16: 5433–5444.
20. Mays RW, Siemers KA, Fritz BA, Lowe AW, van Meer G, et al. (1995)
Hierarchy of mechanisms involved in generating Na/K-ATPase polarity in
MDCK epithelial cells. J Cell Biol 130: 1105–1115.
21. Harris ES, Nelson WJ (2010) VE-cadherin: at the front, center, and sides of
endothelial cell organization and function. Curr Opin Cell Biol 22: 651–658.
22. Mimnaugh EG, Bonvini P, Neckers L (1999) The measurement of ubiquitin and
ubiquitinated proteins. Electrophoresis 20: 418–428.
23. Troyanovsky RB, Laur O, Troyanovsky SM (2007) Stable and unstable
cadherin dimers: mechanisms of formation and roles in cell adhesion. Mol Biol
Cell 18: 4343–4352.
24. Ishiyama N, Lee SH, Liu S, Li GY, Smith MJ, et al. (2010) Dynamic and static
interactions between p120 catenin and E-cadherin regulate the stability of cell-
cell adhesion. Cell 141: 117–128.
Regulation of E-Cadherin Degradation
PLoS ONE | www.plosone.org 13 May 2012 | Volume 7 | Issue 5 | e3747625. Chen YT, Stewart DB, Nelson WJ (1999) Coupling assembly of the E-cadherin/
beta-catenin complex to efficient endoplasmic reticulum exit and basal-lateral
membrane targeting of E-cadherin in polarized MDCK cells. J Cell Biol 144:
687–699.
26. Marrs JA, Napolitano EW, Murphy-Erdosh C, Mays RW, Reichardt LF, et al.
(1993) Distinguishing roles of the membrane-cytoskeleton and cadherin
mediated cell-cell adhesion in generating different Na+,K(+)-ATPase distribu-
tions in polarized epithelia. J Cell Biol 123: 149–164.
Regulation of E-Cadherin Degradation
PLoS ONE | www.plosone.org 14 May 2012 | Volume 7 | Issue 5 | e37476